Combining causal and correlative approaches to discover response biomarkers to paclitaxel.

A recent research paper published in Oncotarget discusses the discovery of a potential biomarker, SSR3, that could predict the response to paclitaxel treatment in glioblastoma and breast cancer patients. The researchers used a whole genome CRISPR knockout screen to identify this biomarker, and it was validated in two independent breast cancer patient cohorts. The paper emphasizes the importance of validating novel biomarkers to improve the efficacy of therapeutic agents, particularly in the context of glioblastoma where treatment outcomes can be unpredictable. The researchers also highlight the need for further identification and validation of predictive biomarkers to enable personalized and precise medicine. [Extracted from the article]